IN STENT RESTENOSIS (ISR) IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR CORONARY ARTERY DISEASE (CAD)

S ULLAH; MH ARSHAD; J HUSSAIN

doi:10.54112/bcsrj.v2024i1.826

Authors

S ULLAH Cardiologist Health Department KPK, Pakistan
MH ARSHAD Wah Medical College Wah Cantt, Hospital POF Hospital Wah Cantt, Pakistan
J HUSSAIN Department of Cardiology Sheikh Zayed Hospital Rahim Yar Khan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.826

Keywords:

In-Stent Restenosis, Percutaneous Coronary Intervention, Coronary Artery Disease, Angiography, Cross-Sectional Studies

Abstract

In-stent restenosis (ISR) remains a significant clinical challenge in patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease (CAD). Objectives: The main aim of the study is to find the In-Stent Restenosis (ISR) in patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease (CAD). Methods: This cross-sectional study was conducted at Prime Teaching Hospital Peshawar from January 2023 till December 2023. Data were collected from 80 patients from both genders. Patients who underwent PCI for CAD and developed ISR, as confirmed by angiographic or intravascular imaging studies, were included. Data were collected in a systematically designed performance. Information was collected from electronic medical records, angiographic reports, and procedural databases. Results: Data were collected from 80 patients according to inclusion criteria. The mean age of the patients was 65.09±8.5 years. There were 52 (65%) male and 48 (35%) female patients. Hypertension was present in 60 (75%), dyslipidemia in 48(60%) and DM in 36 (45%) patients. There was a significant association between older age and increased likelihood of ISR development post-PCI (Mean age ISR: 68.01 ± 7.2 years vs. No ISR: 62.39 ± 9.1 years, p=0.02). However, gender did not significantly influence ISR occurrence (71% male ISR vs. 62% male No ISR, p=0.42). Conclusion: It is concluded that ISR represents a significant challenge in patients post-PCI for CAD, with a substantial incidence observed in this study. Older age, diabetes mellitus, and DES implantation were identified as essential contributors to ISR development.

Downloads

Download data is not yet available.

References

Li M, Hou J, Gu X, Weng R, Zhong Z, Liu S. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China. Eur J Med Res. 2022 Jan 22;27(1):12. doi: 10.1186/s40001-022-00640-z. PMID: 35065663; PMCID: PMC8783476.

Zivelonghi C, et al. Drug-coated balloon: long-term outcome from a real-world three-centre experience. J Interv Cardiol. 2017;30(4):318–324. doi: 10.1111/joic.12391.

Grines CL, Harjai KJ, Schreiber TL. Percutaneous coronary intervention: 2015 in review. J Interv Cardiol. 2016;29(1):11–26. doi: 10.1111/joic.12272.

Zhang DM, Chen S. In-stent restenosis and a drug-coated balloon: insights from a clinical therapeutic strategy on coronary artery diseases. Cardiol Res Pract. 2020;2020:8104939

Nicolais C, et al. Therapeutic options for in-stent restenosis. Curr Cardiol Rep. 2018;20(2):7. doi: 10.1007/s11886-018-0952-4.

Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. J Geriatr Cardiol. 2018;15(2):173–184.

Alraies MC, et al. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017;9(8):640–651. doi: 10.4330/wjc.v9.i8.640.

Yilmaz S, et al. Evaluation of the predictive value of CHA2DS2-VASc score for in-stent restenosis. Angiology. 2018;69(1):38–42. doi: 10.1177/0003319717700746.

Raja, W., Samore, N. A., Saif, M., Kamran, J., Waheed, S., Tariq, N., ... & Siddiqui, A. H. (2020). IN STENT RESTENOSIS (ISR) IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR CORONARY ARTERY DISEASE (CAD). Pakistan Armed Forces Medical Journal, 70(Suppl-4), S865-70.

Moussa, I. D., Mohananey, D., Saucedo, J., Stone, G. W., Yeh, R. W., Kennedy, K. F., ... & Simonton, C. (2020). Trends and outcomes of restenosis after coronary stent implantation in the United States. Journal of the American College of Cardiology, 76(13), 1521-1531.

Tamez, H., Secemsky, E. A., Valsdottir, L., Moussa, I., Song, Y., Simonton, C., ... & Yeh, R. W. (2021). Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries: Long-term outcomes of ISR PCI. EuroIntervention, 17(5), e380.

Alexandrescu, D. M., Mitu, O., Costache, I. I., Macovei, L., Mitu, I., Alexandrescu, A., & Arsenescu Georgescu, C. (2021). Risk factors associated with intra-stent restenosis after percutaneous coronary intervention. Experimental and Therapeutic Medicine, 22(4), 1-7.

Gai, M. T., Zhu, B., Chen, X. C., Liu, F., Xie, X., Gao, X. M., ... & Chen, B. D. (2021). A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents. Lipids in health and disease, 20, 1-9.

Chen, T., Sun, J. L., & Zhang, J. (2020). The relationship between fibrinogen-to-albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting. Coronary Artery Disease, 31(7), 586-589.

Luo, Y., Tan, N., Zhao, J., & Li, Y. (2022). A nomogram for predicting in-stent restenosis risk in patients undergoing percutaneous coronary intervention: a population-based analysis. International Journal of General Medicine, 2451-2461.

Pepe, M., Napoli, G., Carulli, E., Moscarelli, M., Forleo, C., Nestola, P. L., ... & Favale, S. (2021). Autoimmune diseases in patients undergoing percutaneous coronary intervention: A risk factor for in-stent restenosis? Atherosclerosis, 333, 24-31.

Nozari, Y., Ghorashi, S. M., Alidoust, M., Mortazavi, S. H., Jalali, A., Omidi, N., ... & Amirzadegan, A. R. (2022). In-hospital and 1-year outcomes of repeated percutaneous coronary intervention for in-stent restenosis with acute coronary syndrome presentation. Critical Pathways in Cardiology, 21(2), 87-92.

Elbadawi, A., Dang, A. T., Mahana, I., Elzeneini, M., Alonso, F., Banerjee, S., ... & Mintz, G. S. (2023). Outcomes of Percutaneous Coronary Intervention for In‐Stent Restenosis Versus De Novo Lesions: A Meta‐Analysis. Journal of the American Heart Association, 12(13), e029300.

Oguz, M., Akbulut, T., Saylik, F., Sipal, A., & Erdal, E. (2024). Association of coronary artery severity and late in-stent restenosis: an Angiographic Imaging Study. Angiology, 75(2), 122-130.

Takeuchi, M., Dohi, T., Fukase, T., Nishio, R., Takahashi, N., Endo, H., ... & Minamino, T. (2022). Comparison of clinical outcomes between percutaneous coronary intervention for de novo lesions versus in-stent restenosis lesions. Cardiovascular Intervention and Therapeutics, 1-9.